Latest SMC approvals

The Scottish Medicines Consortium has accepted the following drugs for use within NHS Scotland:

  • Botulinum toxin type A (Botox) for the treatment of focal spasticity, including the treatment of wrist and hand disability due to upper limb spasticity associated with stroke in adults.
  • Dalteparin (Fragmin) for the extended treatment of symptomatic venous thromboembolism (VTE) and prevention of its recurrence in patients with solid tumours. Use is restricted to healthcare professionals experienced in the treatment of VTE.
  • Exenatide (Byetta) for the treatment of type 2 diabetes mellitus in combination with metformin and a glitazone as a third-line pre-insulin treatment option.
  • Pazopanib (Votrient) for use in the first-line treatment of advanced renal cell carcinoma.
  • Sildenafil citrate injection (Revatio) for pulmonary arterial hypertension in patients who are currently prescribed oral sildenafil but who are temporarily unable to take oral medicine, but are otherwise clinically and haemodynamically stable. Use is restricted to cases where it is recommended by specialists in the Scottish Pulmonary Vascular Unit and from the Scottish Adult Congenital Cardiac Service.

The SMC rejected adapalene/benzoyl peroxide gel (Epiduo) for the treatment of acne vulgaris and vinflunine (Javlor) for advanced or metastatic transitional cell carcinoma of the urothelial tract on the grounds of insufficient value for money.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more